| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A502 | PDL241 Featured |
|
|
| A503 | Elotuzumab Featured | Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents. |
|
| A504 | Idactamab Featured | Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5). |
|
| A505 | VB1-050 Featured |
|
|
| A506 | LY2928057 Featured |
|
|
| A507 | Amgen patent anti-Ferroportin Featured |
|
|
| A508 | ASG-5ME Featured |
|
|
| A509 | Agilvax Patent Anti-Slc7A11 Featured |
|
|
| A510 | Sirtratumab Featured | Sirtratumab is a human Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). Sirtratumab can be used in research of cancer. |
|
| A511 | Latozinemab Featured | Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research. |
|
| A512 | Blosozumab Featured | Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis. |
|
| A513 | Setrusumab Featured | Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer. |
|
| A514 | Romosozumab Featured | Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis. |
|
| A515 | Sonepcizumab Featured | Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC). |
|
| A516 | Expression DD patent anti-SIP Featured |
|
|
| A517 | Bexmarilimab Featured | Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer. |
|
| A518 | vandortuzumAb Featured |
|
|
| A519 | Genentech patent anti-STOP-1 Featured |
|
|
| A520 | Indatuximab Featured |
|
|
| A521 | Genentech patent anti-TAT226 Featured |
|
|
| A522 | Zagotenemab Featured | Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research. |
|
| A523 | Tilavonemab Featured | Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research. |
|
| A524 | Semorinemab Featured | Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease. |
|
| A525 | Bepranemab Featured | Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research. |
|
| A526 | Gosuranemab Featured | Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD). |
|
| A527 | LY3022859 (IMC-TR1) Featured |
|
|
| A528 | TOL101 Featured |
|
|
| A529 | Anti-TCR Antibody (NKTT320) Featured |
|
|
| A530 | Ontuxizumab Featured | Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer. |
|
| A531 | Fox Chase patent anti-TEM7R Featured |
|
